Bempegaldesleukin (<scp>BEMPEG</scp>; <scp>NKTR</scp>‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
Marlene Hennessy(Nektar Therapeutics (United States)), Nancy Gordon(The University of Texas MD Anderson Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States)), Andrew Wahba(Memorial Hermann), Willem W. Overwijk(Weatherford College), Vidya Gopalakrishnan(The University of Texas MD Anderson Cancer Center), Maria Gabriela Segura(Memorial Hermann), V. Behrana Jensen(The University of Texas MD Anderson Cancer Center), Loui Madakamutil(Nektar Therapeutics (United States)), Vikas Kundra(The University of Texas MD Anderson Cancer Center), Eugenie S. Kleinerman(The University of Texas MD Anderson Cancer Center), Mariella Cabrera(Lincoln Medical Center), Grace Kim(University of California, San Francisco), Murali K. Ravoori(The University of Texas MD Anderson Cancer Center), Rhoneil Pena(Nektar Therapeutics (United States)), Saul Kivimäe(Nektar Therapeutics (United States)), Kumar Felix(Hampton University), John Stewart(Bournemouth University)
Cited by 20
Related Papers
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403